
    
      The study objective is to compare the efficacy and safety of oral propranolol in comparison
      with oral nadolol in patients with IH. Patients will be randomly assigned to either
      propranolol or dose equivalent nadolol. The duration of the study will be 24 weeks, however,
      patient will be monitored for up to 1 year post study enrolment. Both efficacy and safety
      will be closely monitored and captured.
    
  